- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07940101
Clinical and Electrophysiological Heterogeneity in Adult Charcot-Marie-Tooth Disease
Clinical and Electrophysiological Heterogeneity in Adult Charcot-Marie-Tooth Disease: An Observational Study of the Relationships Between CMTES-v2, Nerve Conduction Parameters, and Functional Capacity
CMT-PROFILE is a single-center, cross-sectional observational study involving adults with Charcot-Marie-Tooth disease (CMT). The study will investigate the association between clinical disease severity, measured using the CMT Examination Score version 2 (CMTES-v2), and motor electrophysiological parameters, including compound muscle action potential (CMAP) amplitudes and motor nerve conduction velocities. Secondary objectives include characterizing clinical-electrophysiological concordance, comparing functional capacity, muscle strength and mobility across concordance groups, and exploring demographic, clinical, biological and genetic factors associated with variability in disease expression. Approximately 250 patients are planned for inclusion. All assessments will be performed at a single reference time point (M0), with no longitudinal follow-up.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Abderhmane Slioui
- Telefonnummer: +33 0492038953
- E-post: slioui.a@chu-nice.fr
Studer Kontakt Backup
- Navn: Angela Puma
- Telefonnummer: +33 0492035435
- E-post: puma.ar@chu-nice.fr
Studiesteder
-
-
Alpes Maritimes
-
Nice, Alpes Maritimes, Frankrike, 06000
- CHU de Nice
-
Ta kontakt med:
- Abderhmane Slioui
- Telefonnummer: +33 0492038953
- E-post: slioui.a@chu-nice.fr
-
Ta kontakt med:
- Angela de Nice
- Telefonnummer: +33 0492035435
- E-post: puma.ar@chu-nice.fr
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Adults with Charcot-Marie-Tooth disease evaluated at the Peripheral Neuromuscular Rare Disease Reference Center of Nice University Hospital. The study aims to characterize the relationships between clinical disease severity, assessed using the CMTES-v2, motor electrophysiological parameters, and functional capacity. Participants will undergo a single reference assessment (M0), with no subsequent follow-up. The planned sample size is approximately 250 participants, subject to confirmation against the approved protocol.
Beskrivelse
Inclusion Criteria:
- Adults aged 18 years or older.
- Diagnosis of peripheral sensory polyneuropathy.
- Classification as length-dependent (LDN) or non-length-dependent (NLDN) based on clinical and electrophysiological findings.
- Available nerve conduction study including sural and radial sensory nerve amplitudes allowing calculation of the SRAR.
- Evaluated at the Peripheral Neuromuscular Rare Disease Reference Center, Nice University Hospital, between January 2013 and July 2026.
Exclusion Criteria:
- Missing or incomplete clinical or electrophysiological data preventing SRAR calculation.
- Unclassifiable neuropathy phenotype.
- Technical factors affecting the reliability of nerve conduction studies.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: CROSS_SECTIONAL
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Adults with Charcot-Marie-Tooth Disease
|
This observational, cross-sectional study evaluates clinical severity, electrophysiological parameters, and functional capacity in adults with Charcot-Marie-Tooth disease (CMT). Data collected at a single reference time point (M0) include the CMT Examination Score version 2 (CMTES-v2), nerve conduction study parameters, including compound muscle action potential (CMAP) amplitudes and motor nerve conduction velocities, and available functional and clinical measures. Additional variables may include muscle strength, mobility, pain, patient-perceived disease severity, occupational impact, and demographic, clinical, and genetic characteristics, as specified in the study protocol. No study-specific treatment or intervention is administered. There is no longitudinal follow-up |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Association Between CMTES-v2 and Motor Electrophysiological Parameters
Tidsramme: At day 0 (single assessment; no follow-up).
|
To assess the association between the CMTES-v2 total score and prespecified motor electrophysiological parameters, including distal CMAP amplitudes and motor nerve conduction velocities, using correlation analyses as specified in the statistical analysis plan. |
At day 0 (single assessment; no follow-up).
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical-Electrophysiological Concordance and Discordance Classification
Tidsramme: At Day 0 (single assessment; no follow-up).
|
disease severity and electrophysiological impairment, using standardized residuals derived from the difference between observed CMTES-v2 scores and scores predicted from motor electrophysiological parameters, divided by the residual standard deviation. Patients will be classified into three mutually exclusive categories: concordant (standardized residual between -1.96 and +1.96), greater clinical severity than predicted (standardized residual above +1.96), or lower clinical severity than predicted (standardized residual below -1.96). Results will be expressed as the number and percentage of patients in each category. |
At Day 0 (single assessment; no follow-up).
|
|
Age at Assessment Across Clinical-Electrophysiological Concordance Groups
Tidsramme: At Day 0 (single assessment; no follow-up)
|
To investigate whether age at clinical assessment differs according to the degree of clinical-electrophysiological concordance, age will be recorded in years and compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up)
|
|
Age at Symptom Onset Across Clinical-Electrophysiological Concordance Groups
Tidsramme: At Day 0 (single assessment; no follow-up)
|
To investigate whether age at clinical assessment differs according to the degree of clinical-electrophysiological concordance, age will be recorded in years and compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up)
|
|
Disease Duration Across Clinical-Electrophysiological Concordance Groups
Tidsramme: At Day 0 (single assessment; no follow-up)
|
To evaluate the relationship between disease duration and clinical-electrophysiological concordance, disease duration will be calculated as the interval, expressed in years, between the reported onset of symptoms and the reference clinical assessment. Disease duration will be compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up)
|
|
Genetic Subtype Distribution Across Clinical-Electrophysiological Concordance Groups
Tidsramme: At Day 0 (single assessment; no follow-up)
|
To investigate whether the distribution of genetically confirmed Charcot-Marie-Tooth disease subtypes differs according to clinical-electrophysiological concordance, genetic subtypes documented in the medical records will be categorized and compared across the three predefined concordance groups. Results will be reported as the number and percentage of patients within each genetic subtype among those with available genetic data. |
At Day 0 (single assessment; no follow-up)
|
|
Functional Performance Across Clinical-Electrophysiological Concordance Groups (CMT-FOM)
Tidsramme: At Day 0 (single assessment; no follow-up).
|
To evaluate whether functional performance differs according to clinical-electrophysiological concordance, functional capacity will be quantified using the total score of the Charcot-Marie-Tooth Functional Outcome Measure (CMT-FOM). Scores will be compared across the three predefined concordance groups among patients with available assessments. |
At Day 0 (single assessment; no follow-up).
|
|
Muscle Strength Across Clinical-Electrophysiological Concordance Groups (MRC Scale)
Tidsramme: At Day 0 (single assessment; no follow-up)
|
To assess differences in muscle strength according to clinical-electrophysiological concordance, muscle strength will be evaluated using the Medical Research Council (MRC) grading scale, ranging from 0 (no visible or palpable muscle contraction) to 5 (normal muscle strength). Recorded muscle strength grades will be compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up)
|
|
Right Handgrip Strength Across Clinical-Electrophysiological Concordance Groups
Tidsramme: At Day 0 (single assessment; no follow-up)
|
To assess differences in right handgrip strength according to clinical-electrophysiological concordance, right handgrip strength will be measured by dynamometry, with the highest value obtained from three trials retained for analysis. Measurements will be compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up)
|
|
Left Handgrip Strength Across Clinical-Electrophysiological Concordance Groups
Tidsramme: At Day 0 (single assessment; no follow-up).
|
To assess differences in left handgrip strength according to clinical-electrophysiological concordance, left handgrip strength will be measured by dynamometry, with the highest value obtained from three trials retained for analysis. Measurements will be compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up).
|
|
Functional Mobility Across Clinical-Electrophysiological Concordance Groups (Timed Up and Go)
Tidsramme: At Day 0 (single assessment; no follow-up)
|
To investigate differences in functional mobility according to clinical-electrophysiological concordance, mobility will be assessed using the Timed Up and Go (TUG) test, measuring the time required to rise from a chair, walk three meters, turn, return to the chair and sit down. Completion time will be recorded in seconds and compared across the three predefined concordance groups. Inability to complete the test safely will be recorded as a non-feasible assessment rather than assigned an arbitrary completion time. |
At Day 0 (single assessment; no follow-up)
|
|
Pain Intensity Across Clinical-Electrophysiological Concordance Groups
Tidsramme: At Day 0 (single assessment; no follow-up).
|
To investigate whether pain intensity differs according to clinical-electrophysiological concordance, average pain intensity over the preceding seven days will be assessed using an 11-point numerical rating scale, ranging from 0 (no pain) to 10 (worst imaginable pain). Pain scores will be compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up).
|
|
Patient-Perceived Disease Severity Across Clinical-Electrophysiological Concordance Groups
Tidsramme: At Day 0 (single assessment; no follow-up)
|
To evaluate differences in patient-perceived disease severity according to clinical-electrophysiological concordance, overall disease severity will be self-rated using a five-point ordinal scale ranging from 1 (very mild) to 5 (very severe). Scores will be compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up)
|
|
Work Absenteeism Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
Tidsramme: At Day 0 (single assessment; no follow-up)
|
To investigate differences in work absenteeism associated with Charcot-Marie-Tooth disease according to clinical-electrophysiological concordance, absenteeism will be assessed using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) and quantified as the percentage of working time missed due to the disease during the preceding seven days, ranging from 0% to 100%. Comparisons will be performed across the three predefined concordance groups among employed participants for whom the measure is applicable. |
At Day 0 (single assessment; no follow-up)
|
|
Work Presenteeism Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
Tidsramme: At Day 0 (single assessment; no follow-up).
|
To investigate differences in work-related productivity impairment while present at work according to clinical-electrophysiological concordance, presenteeism will be assessed using the WPAI:SHP questionnaire and expressed as the percentage of impairment while working attributable to Charcot-Marie-Tooth disease during the preceding seven days, ranging from 0% to 100%. Results will be compared across the three predefined concordance groups among participants for whom the measure is applicable. |
At Day 0 (single assessment; no follow-up).
|
|
Overall Work Productivity Impairment Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
Tidsramme: At Day 0 (single assessment; no follow-up).
|
To assess whether overall work productivity impairment differs according to clinical-electrophysiological concordance, overall impairment will be calculated from the absenteeism and presenteeism components of the WPAI:SHP questionnaire and expressed as a percentage ranging from 0% (no impairment) to 100% (complete impairment) over the preceding seven days. Results will be compared across the three predefined concordance groups among participants for whom the measure is applicable |
At Day 0 (single assessment; no follow-up).
|
|
Daily Activity Impairment Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
Tidsramme: At Day 0 (single assessment; no follow-up)
|
To assess differences in the impact of Charcot-Marie-Tooth disease on usual daily activities according to clinical-electrophysiological concordance, activity impairment will be quantified using the WPAI:SHP questionnaire and expressed as a percentage ranging from 0% (no impairment) to 100% (complete impairment) over the preceding seven days. Results will be compared across the three predefined concordance groups, irrespective of employment status |
At Day 0 (single assessment; no follow-up)
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Angela Puma, Centre Hospitalier Universitaire de Nice
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i nervesystemet
- Nevromuskulære sykdommer
- Genetiske sykdommer, medfødte
- Sykdommer i det perifere nervesystemet
- Nevrodegenerative sykdommer
- Medfødte abnormiteter
- Heredodegenerative lidelser, nervesystemet
- Misdannelser i nervesystemet
- Polynevropatier
- Arvelig sensorisk og motorisk nevropati
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Charcot-Marie-tann sykdom
Andre studie-ID-numre
- 26Neuro06
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .